MPLN expands their oncology offering in CLL/SLL with IgVH Somatic Hypermutation by NGS

Posted on October 19 2016 by Jonathan Mulkey

CLL/SLL is the most common leukemia diagnosed among adults in Western countries and is associated with heterogeneous clinical outcomes.  IgVH somatic hypermutation (SHM) status is a primary component of the CLL International Prognostic Index…
Read more


MPLN partners with ArcherDX to offer ArcherĀ® NGS assays to global biopharma

Posted on July 19 2016 by J Seabrook

Boulder, COLORADO – ArcherDX, Inc., has announced that Molecular Pathology Laboratory Network, Inc. (MPLN) is now a Certified Service Provider of Archer® FusionPlex® NGS assays. MPLN will offer a custom sarcoma analysis service that…
Read more

MPLN Expands Cystic Fibrosis Offering with Mutation Detection by Next Generation Sequencing

Posted on June 29 2016 by J Seabrook

MPLN expands cystic fibrosis offering with a comprehensive range of molecular testing options to support all clinically relevant indications for CFTR testing. MPLN’s offering includes testing for screening, diagnostic and therapeutic applications…
Read more

MPLN expands Next Generation Sequencing offering with Solid Tumor Panels

Posted on September 28 2015 by J Seabrook

MARYVILLE, Tenn. – (Sept 17, 2015) – Molecular Pathology Laboratory Network (MPLN) today announced that it is expanding its integrated oncology specialty testing offering to include Next Generation Sequencing assays for solid tumor. The…
Read more


Advancing Pathology and Cancer Research with NGS illumina Webinar Sep 23rd 2015

Posted on September 14 2015 by J Seabrook

Join Jamie Platt PhD, Vice President, Genomic Solutions, for a webinar on Advancing Pathology and Cancer research as she discusses the benefits of integrating NGS into clinical oncology research.

Dr. Platt will present an overview of the utility,…
Read more

1 2 3